Protein Tyrosine Phosphatase PTPN22 +1858C/T Polymorphism is Associated with Active Vitiligo

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2014 Oct 8

PMID 25289035

Citations 11

Authors

Martha Elena Garcia-Melendez

Mauricio Salinas-Santander

Celia Sanchez-Dominguez

Hugo Gonzalez-Cardenas

Ricardo M Cerda-Flores

Jorge Ocampo-Candiani

Rocio Ortiz-Lopez

Affiliations

Soon will be listed here.

Abstract

Vitiligo is characterized by a skin depigmentation disorder resulting from an autoimmune response targeting melanocytes. Within the genetic factors involved in the development of the vitiligo immune response, various genes in the major histocompatibility complex (MHC) and non-MHC loci have been considered to be risk factors. The gene encodes for a lymphoid protein tyrosine phosphatase, a regulator of the activation and development of T-cells. The polymorphism has been associated to autoimmune disease susceptibility in different populations and could be implicated in the onset of vitiligo. To assess the possible association between the presence of and vitiligo, 187 patients with vitiligo and 223 control subjects were analyzed in the study. Genomic DNA was isolated using the salting-out method and samples were subjected to polymerase chain reaction-restriction fragment length polymorphism in order to detect the polymorphism. Causal associations were determined by χ test and their respective odds ratio (OR) was assessed in a 2×2 contingency table. The results showed an association between active vitiligo and the allele T load [P=0.0418; OR, 2.5706; 95% confidence interval (CI), 1.0040-6.5816], and active vitiligo-CT genotype (P=0.0389, OR, 2.6548; 95% CI, 1.0191-6.9156). In conclusion, the present data indicates a possible association between the genotype and a significant susceptibility of developing an active form of vitiligo.

Citing Articles

Evaluation of polymorphisms and expression of , and genes in vitiligo patients.

Mecinska-Jundzill K, Tadrowski T, Jundzill A, Witmanowski H, Czajkowki R Postepy Dermatol Alergol. 2023; 40(2):225-233.

PMID: 37312906 PMC: 10258693. DOI: 10.5114/ada.2023.126314.

Whole Exome Sequencing Reveals Clustering of Variants of Known Vitiligo Genes in Multiplex Consanguineous Pakistani Families.

Ishaq R, Ilyas M, Habiba U, Amin M, Saeed S, Raja G Genes (Basel). 2023; 14(5).

PMID: 37239478 PMC: 10218579. DOI: 10.3390/genes14051118.

Association between the CTLA4 +49A/G (rs231775) and CT60 (rs3087243) gene variants with vitiligo: study on a Mexican population.

Salinas-Santander M, de Jesus Suarez-Valencia V, Angel-Martinez M, Kubelis-Lopez D, Zapata-Salazar N, Ocampo-Garza J An Bras Dermatol. 2022; 97(6):710-715.

PMID: 36163113 PMC: 9583029. DOI: 10.1016/j.abd.2021.10.012.

Novel immunological and genetic factors associated with vitiligo: A review.

Said-Fernandez S, Sanchez-Dominguez C, Salinas-Santander M, Martinez-Rodriguez H, Kubelis-Lopez D, Zapata-Salazar N Exp Ther Med. 2021; 21(4):312.

PMID: 33717255 PMC: 7885061. DOI: 10.3892/etm.2021.9743.

Association of Functional Polymorphism in Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Gene with Vitiligo.

Huraib G, Al Harthi F, Arfin M, Aljamal A, Alrawi A, Al-Asmari A Biomark Insights. 2020; 15:1177271920903038.

PMID: 32076368 PMC: 7003175. DOI: 10.1177/1177271920903038.

References

Parsad D, Dogra S, Kanwar A . Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003; 1:58. PMC: 269995. DOI: 10.1186/1477-7525-1-58. View

Zhang X, Chen J, Liu J . The genetic concept of vitiligo. J Dermatol Sci. 2005; 39(3):137-46. DOI: 10.1016/j.jdermsci.2005.06.004. View

Huggins R, Janusz C, Schwartz R . Vitiligo: a sign of systemic disease. Indian J Dermatol Venereol Leprol. 2006; 72(1):68-71. DOI: 10.4103/0378-6323.19730. View

Vang T, Miletic A, Bottini N, Mustelin T . Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 2007; 40(6):453-61. DOI: 10.1080/08916930701464897. View

Wang C, Cruz-Inigo A, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M . Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One. 2011; 6(4):e18907. PMC: 3081835. DOI: 10.1371/journal.pone.0018907. View

Shajil E, Chatterjee S, Agrawal D, Bagchi T, Begum R . Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. Indian J Exp Biol. 2006; 44(7):526-39. View

Burn G, Svensson L, Sanchez-Blanco C, Saini M, Cope A . Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?. FEBS Lett. 2011; 585(23):3689-98. DOI: 10.1016/j.febslet.2011.04.032. View

Sandoval-Cruz M, Garcia-Carrasco M, Sanchez-Porras R, Mendoza-Pinto C, Jimenez-Hernandez M, Munguia-Realpozo P . Immunopathogenesis of vitiligo. Autoimmun Rev. 2011; 10(12):762-5. DOI: 10.1016/j.autrev.2011.02.004. View

Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A, Weiss A . PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol. 2009; 182(7):4093-106. PMC: 2765978. DOI: 10.4049/jimmunol.0803317. View

10.

LaBerge G, Birlea S, Fain P, Spritz R . The PTPN22-1858C>T (R620W) functional polymorphism is associated with generalized vitiligo in the Romanian population. Pigment Cell Melanoma Res. 2008; 21(2):206-8. DOI: 10.1111/j.1755-148X.2008.00443.x. View

11.

Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman C . Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood. 1999; 93(6):2013-24. View

12.

Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, Meng X . The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet. 2011; 43(9):902-7. DOI: 10.1038/ng.904. View

13.

Chen Y, Chang J . PTPN22 C1858T and the risk of psoriasis: a meta-analysis. Mol Biol Rep. 2012; 39(8):7861-70. DOI: 10.1007/s11033-012-1630-z. View

14.

Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M . A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004; 36(4):337-8. DOI: 10.1038/ng1323. View

15.

Almeida P, Borrego L, Rodriguez-Lopez J, Lujan D, Cameselle D, Hernandez B . [Vitiligo. Treatment of 12 cases with topical tacrolimus]. Actas Dermosifiliogr. 2006; 96(3):159-63. DOI: 10.1016/s0001-7310(05)73058-1. View

16.

Cenit M, Marquez A, Cordero-Coma M, Fonollosa A, Llorenc V, Artaraz J . Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis. Mol Vis. 2013; 19:638-43. PMC: 3611931. View

17.

Sehgal V, Srivastava G . Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007; 73(3):149-56. DOI: 10.4103/0378-6323.32708. View

18.

Harrison P, Pointon J, Farrar C, Brown M, Wordsworth B . Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients. Rheumatology (Oxford). 2006; 45(8):1009-11. DOI: 10.1093/rheumatology/kei250. View

19.

Song G, Kim J, Lee Y . The CTLA-4 +49 A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis. Mol Biol Rep. 2012; 40(4):2985-93. DOI: 10.1007/s11033-012-2370-9. View

20.

Kemp E, Gavalas N, Gawkrodger D, Weetman A . Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev. 2007; 6(3):138-42. DOI: 10.1016/j.autrev.2006.09.010. View